Nicola Dagg is a partner in the IP litigation team in the London office of Kirkland & Ellis International LLP. Nicola’s practice spans four areas: (1) strategic life sciences patent and product lifecycle advice; (2) patent litigation; (3) co-ordinating global IP enforcement/defence cases; and (4) standard essential patent (SEP) and FRAND disputes. Nicola has tried over 20 cases.
Nicola has extensive experience in pharmaceutical and biologics patent litigation including blockbuster small molecule litigation against generic companies, biologics and biosimilar litigation, antibodies, immunotherapies, genetics, vaccines, diagnostics and gene therapies. Nicola also acts in market leading SEP essentiality, validity and global FRAND adjudication litigation in the tech sector. Having served as UK and European/global co-ordinating counsel for numerous strategic IP litigation cases and drawing on more than 24 years of legal, IP, life sciences and tech experience she helps clients solve their most pressing global challenges.
Nicola writes and speaks extensively on intellectual property litigation. She was named Lawyer of the Year 2017 for Life Sciences (Patent Litigation); she is ranked as a leading IP partner in Chambers Global, Chambers UK and Legal 500. Chambers Global 2020 recognises Nicola as a “pre-eminent” litigator who is “fantastic – extremely strategic, laser-focused and gets the right results for her clients”. Nicola has also been selected as one of the 10 “Most Highly Regarded Individuals” in Europe by Who’s Who Legal: Patents 2016 and was named as one of the “Top 50 women lawyers in London” in the 2015 Super Lawyers list. Who’s Who Legal has listed Nicola as an expert in each of Patent Lawyers, Life Sciences patent litigation and as a Thought Leader for life sciences.
Nicola has consistently been recognised as a gold-ranked patent litigator by IAM Patent 1000 and in their 2019 directory they describe her as “fantastic – the driving force in what is one of the great success stories in recent years” and acknowledge her “impressive” team-building and client-handling skills.
Dagg, N., Baldwin, S., Coltart, K., and Shandler, B. (2021) “Patent Litigation 2021: Trends and Developments”, Chambers and Partners Practice Guides
Dagg, N., Lim, D., Baldwin, S., and Bornstein, G. (2020) “Trade Secrets 2020: Law and Practice”, Chambers and Partners Practice Guides
Dagg, N., Lim, D., Shandler, B., and Kritharidis, A. (2020) “Patent Litigation 2020: Trends and Developments”, Chambers and Partners Practice Guides
Dagg, N., Coltart, K., Lim, D., and Ooi, J. (2019) “Patent Litigation 2019: Trends and Developments”, Chambers and Partners Practice Guides
Dagg, N., Baldwin, S., and Rollins, T. (2017) “From Takeda to Teva v Merck: Are we treading the right path on combination products SPC’s? (Part 2 of 2)”, European Intellectual Property Review
Dagg, N., Baldwin, S., and Rollins, T. (2017) “The definition of product in the SPC Regulation: What’s in a name? (Part 1 of 2)”, European Intellectual Property Review
Dagg, N. (2014) UK chapter in “Copyright litigation - Jurisdictional comparisons 2nd edition”, Thomson Reuters
Dagg, N. (2013) “Second medical use”, The International Who’s Who of Patent Lawyers
Dagg, N. (2010) UK chapter in “Copyright Litigation – Jurisdictional comparisons”, Thomson Reuters
Regulatory issues key for life sciences in Brexit debate. Life Sciences Review (25 August 2017)
Life Sciences Patent Network Europe, Life Sciences Review (20 December 2016)
Admissions & Qualifications
- 1996, Admitted to Practice as a Solicitor of England and Wales
- Solicitor Advocate, Higher Court (Civil Proceedings)
- Admitted to the Law Society of Ireland
- Newnham College, University of CambridgeM.A., Natural Sciences1991
- University of BristolDiploma in Intellectual Property Law and Practice1997